Duopharma Biotech Bhd is on track for a record-breaking profit year, with earnings anticipated to increase by over 40%.

India's Biocon has expanded its pipeline of biosimilars with a $3.3 billion deal to acquire a portfolio of drugs from Viatris, the parent of its longstanding partner Mylan, which will boost its ...

CSIR NET qualification offers careers in academia, research, government, and industry. Opportunities include PhDs, scientist roles, private-sector R&D, entrepreneurship, consulting, and competitive ...

Conclusion: Revision order issued by PCIT was quashed against Make My Trip (India) Private Limited as AO had conducted a proper inquiry before allowing the deduction of Employee Stock Option Plan ...

AM(IST)on Thursday in an upbeat market. Ipca Laboratories Ltd.(up 1.4 per cent), Divi's Laboratories Ltd.(up 1.35 per cent), ...

She brings over a decade of experience in private equity and technology investments. Singapore-headquartered bolttech has ...

The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.

As of 11:48:15 AM GMT+5:30. Market Open. Loading Chart for BIOCON.NS ...

Get all latest & breaking news on Morning Trade. Watch videos, top stories and articles on Morning Trade at moneycontrol.com.

Return on investment - most recent fiscal year 3.50 ...

GAITHERSBURG, Md., March 19, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has completed the sale of its Baltimore-Bayview drug substance manufacturing ...